SCHEMBL22158123

SCHEMBL22158123

COc1ccc(-c2ccn3ccnc3c2)c2nc(NC(=O)N3CCC(C)(O)CC3)[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 3/20 0.40
▸ ADORA1 P30542 3/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ ADORA2B P29275 1/20 0.40
▸ PIK3C3 Q8NEB9 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CCNT1 O60563 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ OPRD1 P41143 1/20 0.33
▸ OPRK1 P41145 1/20 0.33
▸ CCNC P24863 1/20 0.33
▸ CDK8 P49336 1/20 0.33
▸ CDK19 Q9BWU1 1/20 0.33
▸ PDPK1 O15530 2/20 0.32
▸ MAP4K1 Q92918 1/20 0.32
▸ NPY5R Q15761 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ FAAH O00519 1/20 0.32
▸ HCRTR1 O43613 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29889382 0.84 ADORA2A (0.45) ADORA2AADORA1ADORA3ADORA2BL3MBTL1
SCHEMBL20765033 0.84 ADORA2A (0.45) ADORA2AADORA1ADORA3ADORA2BL3MBTL1
SCHEMBL29889767 0.84 ADORA2A (0.45) ADORA2AADORA1ADORA3ADORA2BL3MBTL1
SCHEMBL20765632 0.83 HCRTR1 (0.44) ADORA2AADORA1ADORA3ADORA2BCCNT1
SCHEMBL29889480 0.83 ADORA2A (0.41) ADORA2AADORA1ADORA3ADORA2BL3MBTL1
SCHEMBL20765074 0.83 ADORA2A (0.41) ADORA2AADORA1ADORA3ADORA2BL3MBTL1
SCHEMBL29889342 0.83 HCRTR1 (0.44) ADORA2AADORA1ADORA3ADORA2BCCNT1
SCHEMBL20765052 0.82 ADORA2A (0.43) ADORA2AADORA1ADORA3ADORA2BCCNT1
SCHEMBL29890474 0.82 ADORA2A (0.43) ADORA2AADORA1ADORA3ADORA2BCCNT1
SCHEMBL22158139 0.82 ADORA3 (0.41) ADORA2AADORA1ADORA3ADORA2BL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP claimed
US-20200207720-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2020-07-02 — — US claimed
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP disclosed
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 — — US disclosed
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2022-09-27 — — US disclosed
US-20200207720-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2020-07-02 — — US disclosed
US-20200207720-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2020-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885
US-20200207720-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback